PMID- 37485388
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230725
IS  - 2296-861X (Print)
IS  - 2296-861X (Electronic)
IS  - 2296-861X (Linking)
VI  - 10
DP  - 2023
TI  - Effects of Lactiplantibacillus plantarum and Lacticaseibacillus paracasei 
      supplementation on the faecal metabolome in children with coeliac disease 
      autoimmunity: a randomised, double-blinded placebo-controlled clinical trial.
PG  - 1183963
LID - 10.3389/fnut.2023.1183963 [doi]
LID - 1183963
AB  - INTRODUCTION: Coeliac disease is a lifelong immune-mediated enteropathy 
      manifested as gluten intolerance in individuals carrying specific human leukocyte 
      antigen (HLA) molecules. Other factors than genetics and gluten intake, however, 
      may play a role in triggering the disease. The gut internal environment is 
      thought to be one of these potential contributing factors, and it can be 
      influenced throughout life. METHODS: We examine the impact of Lactiplantibacillus 
      plantarum HEAL9 and Lacticaseibacillus paracasei 8700:2 supplementation on the 
      faecal metabolome in genetically predisposed children having tissue 
      transglutaminase autoantibodies, i.e., coeliac disease autoimmunity. Probiotic 
      strains were selected based on their beneficial properties, including mucosal 
      permeability and immune modulation effects. The intervention group (n = 40) and 
      control group (n = 38) took the probiotics or placebo daily for 6 months in a 
      double-blinded randomised trial. Faecal samples were collected at baseline and 
      after 3 and 6 months and analysed using the 1H NMR for metabolome. The 
      incorporation of 16S rRNA sequencing as a supportive dataset complemented the 
      analysis of the metabolome data. RESULTS: During the 6 months of intervention, 
      the stool concentrations of 4-hydroxyphenylacetate increased in the intervention 
      group as compared to controls, whereas concentrations of threonine, valine, 
      leucine, isoleucine, methionine, phenylalanine, aspartate, and fumarate 
      decreased. Additionally, a noteworthy effect on the glycine, serine, and 
      threonine metabolic pathway has been observed. CONCLUSION: The findings suggest a 
      modest yet significant impact of the probiotics on the faecal metabolome, 
      primarily influencing proteolytic processes in the gut. CLINICAL TRIAL 
      REGISTRATION: ClinicalTrials.gov, NCT03176095.
CI  - Copyright (c) 2023 Jenickova, Andren Aronsson, Mascellani Bergo, Cinek, Havlik and 
      Agardh.
FAU - Jenickova, Eliska
AU  - Jenickova E
AD  - Department of Food Science, Czech University of Life Sciences Prague, Prague, 
      Czechia.
FAU - Andren Aronsson, Carin
AU  - Andren Aronsson C
AD  - Department of Clinical Sciences, Lund University, Malmo, Sweden.
FAU - Mascellani Bergo, Anna
AU  - Mascellani Bergo A
AD  - Department of Food Science, Czech University of Life Sciences Prague, Prague, 
      Czechia.
FAU - Cinek, Ondrej
AU  - Cinek O
AD  - Department of Pediatrics and Department of Medical Microbiology, Charles 
      University in Prague and University Hospital Motol, Prague, Czechia.
FAU - Havlik, Jaroslav
AU  - Havlik J
AD  - Department of Food Science, Czech University of Life Sciences Prague, Prague, 
      Czechia.
FAU - Agardh, Daniel
AU  - Agardh D
AD  - Department of Clinical Sciences, Lund University, Malmo, Sweden.
LA  - eng
SI  - ClinicalTrials.gov/NCT03176095
PT  - Journal Article
DEP - 20230706
PL  - Switzerland
TA  - Front Nutr
JT  - Frontiers in nutrition
JID - 101642264
PMC - PMC10359497
OTO - NOTNLM
OT  - Lacticaseibacillus paracasei
OT  - Lactiplantibacillus plantarum
OT  - NMR
OT  - coeliac disease
OT  - gut metabolome
OT  - probiotics
COIS- DA was stated as an inventor in a patent application based on the results of the 
      clinical trial but has signed over all legal rights to the patent to Probi AB. 
      Probi AB has developed and supplied the study material (active and placebo 
      products) for the trial as well as financially supported the trial with minor 
      costs for analysing the material. None of the authors are employed by Probi AB 
      and no salaries, consultancy fees, etc. have been paid by Probi AB to the authors 
      in connexion with the trial.
EDAT- 2023/07/24 06:42
MHDA- 2023/07/24 06:43
PMCR- 2023/01/01
CRDT- 2023/07/24 04:57
PHST- 2023/03/10 00:00 [received]
PHST- 2023/06/08 00:00 [accepted]
PHST- 2023/07/24 06:43 [medline]
PHST- 2023/07/24 06:42 [pubmed]
PHST- 2023/07/24 04:57 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fnut.2023.1183963 [doi]
PST - epublish
SO  - Front Nutr. 2023 Jul 6;10:1183963. doi: 10.3389/fnut.2023.1183963. eCollection 
      2023.